JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Linck, B.
Right arrow Articles by Schmitz, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Linck, B.
Right arrow Articles by Schmitz, W.

Vol. 294, Issue 2, 648-657, August 2000

Functional Properties of Transgenic Mouse Hearts Overexpressing Both Calsequestrin and the Na+-Ca2+ Exchanger1

Bettina Linck, Peter Bokník, Sabine Huke, Uwe Kirchhefer, Jörg Knapp, Hartmut Lüss, Frank U. Müller, Joachim Neumann, Zahide Tanriseven, Ute Vahlensieck, Hideo A. Baba, Larry R. Jones, Kenneth D. Philipson and Wilhelm Schmitz

Institut für Pharmakologie und Toxikologie (B.L., P.B., S.H., U.K., J.K., H.L., F.U.M., J.N., Z.T., U.V., W.S.) and Institut für Pathologie (H.A.B.), Westfälische Wilhelms-Universität, Münster, Germany; Krannert Institute of Cardiology and Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana (L.R.J.); and Department of Physiology and Medicine and Cardiovascular Research Laboratories, University of California, Los Angeles, School of Medicine, California (K.D.P.)

Overexpression of calsequestrin (CSQ) induces severe cardiac hypertrophy, whereas overexpression of Na+-Ca2+ exchanger (NCX) does not affect cardiac weight. To investigate a possible beneficial effect of NCX in hypertrophy, we produced transgenic mice overexpressing both NCX and CSQ (NCX/CSQ). Surprisingly, these mice developed severe heart failure. The heart/body weight ratio was enhanced and the mRNA expression of ANF, as a marker of hypertrophy, was highest in double transgenic mice. In isolated muscle strips, the basal relaxation time was prolonged in CSQ and NCX/CSQ mice. Moreover, in the presence of caffeine, force of contraction was increased only in CSQ and NCX/CSQ and was accompanied by elevated diastolic tension. In some respects, however, additional overexpression of NCX altered the CSQ phenotype into the wild-type phenotype. The expression of sarcoplasmic reticulum (SR)-Ca2+-ATPase and phospholamban, proteins involved in the Ca2+ uptake of the SR, were only increased in CSQ, indicating a possible influence of NCX in the regulation of SR-Ca2+ uptake proteins. The Ca2+ transients and the L-type Ca2+ currents in the presence of caffeine were very large in CSQ, but smaller increases were noted in double transgenic mice. Therefore, the successful co-overexpression of CSQ and NCX in these mice provides a novel model in which to investigate the interaction of proteins tightly linked to maintain Ca2+ homeostasis.


1 This work was supported by National Heart, Lung, and Blood Institute Grants HL06308 and HL48509 and the Deutsche Forschungsgemeinschaft (DFG).


0022-3565/00/2942-0648$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
H. Park, I. Y. Park, E. Kim, B. Youn, K. Fields, A. K. Dunker, and C. Kang
Comparing Skeletal and Cardiac Calsequestrin Structures and Their Calcium Binding: A PROPOSED MECHANISM FOR COUPLED CALCIUM BINDING AND PROTEIN POLYMERIZATION
J. Biol. Chem., April 23, 2004; 279(17): 18026 - 18033.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. R Sipido, P. G.A Volders, M. A Vos, and F. Verdonck
Altered Na/Ca exchange activity in cardiac hypertrophy and heart failure: a new target for therapy?
Cardiovasc Res, March 1, 2002; 53(4): 782 - 805.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.